Trials / Completed
CompletedNCT03246880
Clinical Trial To Evaluate the Efficacy and Safety of CKD-397 in Benign Prostatic Hyperplasia Patients
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 455 (actual)
- Sponsor
- Chong Kun Dang Pharmaceutical · Industry
- Sex
- Male
- Age
- 45 Years
- Healthy volunteers
- Not accepted
Summary
A Multicenter, Randomized, Double-blind, Active-controlled, Parallel group, Phase III Clinical Trial To Evaluate the Efficacy and Safety of CKD-397 in Benign Prostatic Hyperplasia Patients.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Tamsulosin 0.2mg | per oral for 12weeks after 2\~4weeks run-in period |
| DRUG | Tadalafil 5mg | per oral for 12weeks after 2\~4weeks run-in period |
Timeline
- Start date
- 2015-09-01
- Primary completion
- 2016-04-01
- Completion
- 2016-05-01
- First posted
- 2017-08-11
- Last updated
- 2017-08-11
Locations
1 site across 1 country: South Korea
Source: ClinicalTrials.gov record NCT03246880. Inclusion in this directory is not an endorsement.